EC Approves Marketing Authorization of AYVAKYT for Patients with PDGFRA D842V Mutant GIST
Pexels / Pixabay

EC Approves Marketing Authorization of AYVAKYT for Patients with PDGFRA D842V Mutant GIST

  Recently, Blueprint Medicines Corporation ("Blueprint") shared that the European Commission (EC) approved marketing authorization of AYVAKYT (avapritinib). The therapy is designed to treat adult patients with PDGFRA D842V mutated gastrointestinal stromal…

Continue Reading EC Approves Marketing Authorization of AYVAKYT for Patients with PDGFRA D842V Mutant GIST
New Treatment Approved in Canada for Gastrointestinal Stromal Tumor
source: pixabay.com

New Treatment Approved in Canada for Gastrointestinal Stromal Tumor

According to a story from Biotech 365, the biopharmaceutical company Deciphera Pharmaceuticals has recently announced that the company's drug ripretinib (marketed as QINLOCK™) has been approved by Health Canada. The…

Continue Reading New Treatment Approved in Canada for Gastrointestinal Stromal Tumor
FDA’s Acceptance of AYVAKIT’s New Drug Application Offers Hope to Metastatic GIST Patients
source: pixabay.com

FDA’s Acceptance of AYVAKIT’s New Drug Application Offers Hope to Metastatic GIST Patients

  Surgery has been found to often be the best option towards a cure for a cancerous tumor (resectable) but there are many other tumors that are diagnosed as unresectable…

Continue Reading FDA’s Acceptance of AYVAKIT’s New Drug Application Offers Hope to Metastatic GIST Patients

Preliminary Phase I Trial Data Released For Experimental Gastronintestinal Stromal Tumor Drug

According to a story from BioPortfolio, the biopharmaceutical company Deciphera Pharmaceuticals, Inc., recently announced the release of preliminary data from the company's Phase I clinical trial, which is still in…

Continue Reading Preliminary Phase I Trial Data Released For Experimental Gastronintestinal Stromal Tumor Drug
#ICYMI: Join the Rare 13 Campaign for Gastrointestinal Stromal Tumors Awareness
Source: Pixabay.com

#ICYMI: Join the Rare 13 Campaign for Gastrointestinal Stromal Tumors Awareness

July 13th was Gastrointestinal Stromal Tumors Awareness Day! And that "13" has extra relevance. 5,000 Americans are diagnosed with Gastrointestinal Stromal Tumors (GIST) each year. That’s 13 people diagnosed each…

Continue Reading #ICYMI: Join the Rare 13 Campaign for Gastrointestinal Stromal Tumors Awareness
Join the Rare 13 Campaign for Gastrointestinal Stromal Tumors Awareness
source: pixabay.com

Join the Rare 13 Campaign for Gastrointestinal Stromal Tumors Awareness

July 13th is Gastrointestinal Stromal Tumors Awareness Day! And that "13" has extra relevance. 5,000 Americans are diagnosed with Gastrointestinal Stromal Tumors (GIST) each year. That’s 13 people diagnosed each day.…

Continue Reading Join the Rare 13 Campaign for Gastrointestinal Stromal Tumors Awareness